Navigation Links
China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
Date:9/10/2008

canker sores;

-- Calcium Folinate injection is intended as an antidote for folic acid

deficiency;

-- Hydrastis suppositories are for the treatment of colds; and

-- The final four drugs, including hemorrhoids gel, hemorrhoids liquids,

chilblain cream and expectorant, are all externally used.

"We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over- the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, object
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
6. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... manufacturing company, announced its financial results for the second quarter ... , Total revenues of $6.5 million in the ... same quarter in 2013 , Total revenues of $13.3 ... increase of 78% over the same period in 2013 ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2
(Date:7/25/2014)... when genes are switched on or off plays a ... regulate metabolism, UT Southwestern Medical Center researchers have found., ... treat obesity and diabetes, since the transcription factor involved ... to influence the body,s sensitivity to insulin and leptin ... body,s regulation of food intake and sugar disposal, and ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Innerspire, LLC ... joined the company as a Creative Enrollment Specialist. In ... relationship building skills as well as his accomplished design ... small business clients, and to service the creative ... Additionally, Greg will work with small business owners and ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) ... CommYOUnity™” during its annual patient and family conference in ... brain tumor community as we – the first and ... services and funding brain tumor research – extend our ... tumor awareness and getting our materials and services into ...
(Date:7/25/2014)... July 25, 2014 There are 700,000 people ... diagnosed each day. Though when someone hears the words, “you ... are unsure of the next step and where to turn. ... figure out that next step by providing and pursuing the ... than Brian Olson, member of the ABTA’s Board of Directors ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... its truth when then Researchers of Arizona University did a ... D.Martinez and collegues , girls who become overweight or obese ... have a sevenfold increased risk of developing asthma .The boys ... if they are obese , the researchers say. , The ...
... research that suggests high doses of vitamin E may ... prevalent diseases in the world with many ravaging complications, ... heart disease, eye damage, kidney failure, non healing ulcers ... of the nervous system. ,Diabetes is caused by ...
... of Pfizer. The pharmaceutical giant has announced that it ... by the AIDS virus. The decision by the Pfizer comes ... a landmark case against pharmaceutical companies. In an announcement ... be given free of cost to battle HIV through a ...
... Azad Medical College, New Delhi has created history of ... from the American patent office for his technique in ... ,A few weeks ago the American patent office granted ... was able to regenerate organs like the uterus, urethra ...
... West is now sitting up and taking in the aroma ... spices are now the subjects of research by scientists at ... C. Fung and colleagues who conducted the study opine that ... can also double up as an anti bacterial agent. ...
... a little quality time with one's spouse and other partners ... pressure. In a study that used portable monitors to ... pressure was lowest when they were with their partners, regardless ... of the State University of New York, the lead study ...
Cached Medicine News: